The Long-term Survival of a Patient with Adenosquamous Lung Carcinoma Harboring EGFR-activating Mutations Who was Treated with Gefitinib

スポンサーリンク

概要

• 論文の詳細を見る

• A 56-year-old woman diagnosed with squamous cell lung carcinoma after a transbronchoscopic examination underwent left upper lobectomy, which revealed a pathological diagnosis of adenosquamous carcinoma containing moderately differentiated squamous cell carcinoma and bronchioloalveolar carcinoma. The epidermal growth factor receptor (EGFR) exon 19 delE746-A750 mutation was detected in deoxyribonucleic acid (DNA) isolated from specimens of both components using microdissection. Treatment with the EGFR tyrosine kinase inhibitor, gefitinib, resulted in a long-term tumor response lasting three years. Adenosquamous carcinoma is difficult to diagnose using transbronchoscopic procedures. Therefore, the examination of EGFR mutation status is important in order to determine the appropriate treatment, even in patients with non-adenocarcinoma.

著者

• Iwanaga Kentaro

  Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan

関連論文

• The Long-term Survival of a Patient with Adenosquamous Lung Carcinoma Harboring EGFR-activating Mutations Who was Treated with Gefitinib

スポンサーリンク